Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese SFDA Deputy Director Under Investigation For Corruption

This article was originally published in PharmAsia News

Executive Summary

BEIJING - A deputy director of China's State FDA is under investigation by the Communist Party's top anti-corruption commission, which could have broad ramifications for the drug agency's daily operations

You may also be interested in...



China FDA Launches Major Enforcement Campaign; Official Cautions Rainy Days Ahead

If a widening anti-bribery investigation, a new drug cost survey and looming pricing reform is not enough, China FDA just launched its first major campaign to root out violations in pharmaceutical manufacturing and distribution. Industry needs to get ready for rainy days, an official cautioned.

China FDA Launches Major Enforcement Campaign; Official Cautions Rainy Days Ahead

If a widening anti-bribery investigation, a new drug cost survey and looming pricing reform is not enough, China FDA just launched its first major campaign to root out violations in pharmaceutical manufacturing and distribution. Industry needs to get ready for rainy days, an official cautioned.

China FDA Launches Major Enforcement Campaign; Official Cautions Rainy Days Ahead

If a widening anti-bribery investigation, a new drug cost survey and looming pricing reform is not enough, China FDA just launched its first major campaign to root out violations in pharmaceutical manufacturing and distribution. Industry needs to get ready for rainy days, an official cautioned.

Related Content

UsernamePublicRestriction

Register

SC075081

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel